Medscape is available in 5 Language Editions – Choose your Edition here.


Light Chain-Associated Renal Disorders Treatment & Management

  • Author: Malvinder S Parmar, MB, MS; Chief Editor: Vecihi Batuman, MD, FACP, FASN  more...
Updated: Nov 21, 2015

Medical Care

The goals of treatment are to prolong survival and to maintain quality of life.

Management of light-chain nephropathy depends on the underlying disease process. Take steps to limit further cast precipitation, and implement effective prevention and management of its complications.


Light-Chain Associated Renal Syndrome

Asymptomatic light-chain proteinuria

See the list below:

  • Idiopathic - No therapy
  • Multiple myeloma - Chemotherapy
  • Waldenström macroglobulinemia - No therapy

Proximal tubular dysfunction (Fanconi syndrome)

See the list below:

  • Associated with myeloma - Chemotherapy
  • Not associated with myeloma - No therapy
  • Metabolic acidosis - Sodium bicarbonate therapy
  • Hypophosphatemia - Phosphate supplementation

Distal tubular dysfunction

See the list below:

  • Distal renal tubular acidosis - Sodium bicarbonate therapy
  • Nephrogenic diabetes insipidus - Thiazide therapy (if no hypercalcemia is present) or correct calcium level (if hypercalcemia is present)


See the list below:

  • Chemotherapy

Acute renal failure

See the list below:

  • Multiple myeloma - The goals of therapy in patients with multiple myeloma and renal failure are to optimize volume status; avoid and treat hypercalcemia, hyperuricemia, and infections; reduce the burden of light chains either by suppressing production with chemotherapy and/or removal of light chains with plasmapheresis or hemodialysis using high-cutoff dialyzers; and dialysis to correct complications of renal failure, as per usual indications.
  • Treat volume depletion with intravenous fluids, hypercalcemia (fluids and Bisphosphonates, preferably pamidronate), hyperuricemia (fluids, xanthine oxidase inhibitors)
  • Chemotherapy (see below) - To suppress light chain production
  • Plasmapheresis (see below) - To remove light chains
  • Dialysis as required
  • Prevent and treat infection

Waldenstrom macroglobulinemia

See the list below:

  • Plasmapheresis for hyperviscosity

Treatment of Primary (Underlying) Disease


Any of the following regimens can be used in patients with multiple myeloma:

  • Melphalan and corticosteroids
  • Combination chemotherapy - VAD (ie, vincristine, Adriamycin, dexamethasone), ABCM (ie, Adriamycin, carmustine [BiCNU], cyclophosphamide, melphalan), or MEVP (ie, melphalan, cyclophosphamide, vincristine, prednisone) [13]
  • Bortezomib, thalidomide, dexamethasone, doxorubicin
  • Interferon alfa 2b

Autologous stem cell transplantation, allogenic or autologous

Myeloablative high-dose chemotherapy and autologous stem cell transplantation induce hematologic remission in a high proportion of patients who are eligible for such treatment, and early results from a limited number of patients suggest that the deterioration of renal function may be arrested and possibly reversed.[14]


Steps to Limit Further Cast Precipitation

These include the following:

  • Rehydration
  • Cessation of nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Treatment of infections
  • Reversal of hypercalcemia

Common Precipitating Factors


This is important in the precipitation of acute renal failure in a significant number (up to 95%) of patients. Dehydration and aciduria favors precipitation of light chains. Ensure adequate hydration of patients, especially before initiating chemotherapy.


Excessive calcium is an important cause of acute renal failure in patients with myeloma and may be present in up to 30% of patients. Hypercalcemia impairs renal concentrating ability, thus leading to dehydration and promoting precipitation of light-chain proteins in renal tubules. Nausea, vomiting, and altered mental state associated with hypercalcemia further increase the likelihood of dehydration. Hypercalciuria also exerts a direct nephrotoxic effect and thus causes tubular degeneration and necrosis. Implement aggressive treatment of hypercalcemia, with saline diuresis, steroids, calcitonin, and diphosphonate.

Contrast-induced renal failure

Perform contrast studies judiciously in patients with multiple myeloma because of the possibility of contrast-induced renal failure. However, McCarthy and Becker reviewed 7 retrospective studies of patients with myeloma who were receiving contrast media and noted that the incidence rate of acute renal failure was only 0.6-1.25%, compared to 0.15% in the general population.[15]


Less Common Precipitating Factors

Nephrotoxic agents

Avoid nephrotoxic agents (eg, NSAIDs, nephrotoxic antibiotics).


Ensure effective treatment of infection (5-20% of patients). Intravenous immunoglobulin has been found to be safe when used as prophylaxis against infection in the so-called plateau phase.


Rare Causes of Acute Renal Failure

Tumor lysis syndrome

Uric acid released following chemotherapy may precipitate in the tubules and may precipitate acute renal failure. Hence, pretreating patients undergoing chemotherapy with allopurinol and diuresis is important.

Nephrolithiasis and urinary tract infections

Treat nephrolithiasis and urinary tract infections promptly.


This can be treated with plasmapheresis.

Myeloma cell infiltration

Treat the underlying process.


Treatment of Complications

Renal failure

Institute dialysis early to avoid uremia compounding the complications of underlying disease. Approximately 20% of patients die within the first month, but predicting which patients will die is not possible. Because 50% of the survivors live longer than 1 year and because recovery of renal function is often delayed for several months, a policy of offering dialysis to most patients is justified. All patients with myeloma who present with acute renal failure should receive dialysis.

Long-term dialysis (hemodialysis or peritoneal dialysis) should be considered for patients with chronic renal failure and myeloma who are responsive to chemotherapy. Before instituting long-term dialysis therapy, consider the extent of other systemic disease. Patients who have progressive myeloma and do not respond to chemotherapy may not be candidates for long-term dialysis because their prognosis is very poor.


The strong association between light-chain excretion and renal failure suggests that light chains play a primary pathogenetic role in producing kidney damage. Plasma exchange appears to be the most efficient way to rapidly remove large amounts of light chains and has been advocated by many over the last 15 years, but its efficacy has not been established convincingly.

Zucchelli et al reported significantly higher survival rates in patients treated with plasma exchange (66% vs 28%, P < .001).[16] In another randomized prospective trial, Johnson et al found no significant difference in the number of patients whose renal function improved with this therapy; however, they noted that patients with severe renal failure improved with plasma exchange.[17]

Clarke et al[18] found no statistically significant difference in the outcomes in a randomized controlled trial; however, this trial had several limitations as there was substantial uncertainty regarding the diagnosis of cast nephropathy because only 61% of the patients had light chains in urine.[19] A retrospective analysis of patients with a diagnosis of cast nephropathy with monitoring of serum light chains to guide therapy showed benefit for plasmapheresis in almost three quarters of the patients,[20] but the benefit of the published data is inconclusive and a well-designed prospective trial is recommended in the future.[21] Complete renal recovery was observed in 40% of patients with early institution of plasmapheresis and bortezomib-based chemotherapy to treat myeloma.[22]

Early and aggressive therapy with 5-7 exchanges within 7-10 days is recommended, and the duration of therapy should be guided by serum free light chains with the aim to reduce light chains by a minimum of 60% for recovery of renal function.[23] Plasmapheresis should be performed in conjunction with dexamethasone and bortezomib-based chemotherapy to reduce light chain production.

High-cutoff dialyzers

Removal of serum free light chains with large-pore (25-50 kd) dialyzers rather than standard high-flux dialyzers has been demonstrated in a pilot study of 19 patients with biopsy proven myeloma kidney, in which 13 of the patients became dialysis-independent within 27 days[24] and 2 trials—European Trial of Free Light Chain Removal by Extended Hemodialysis in Cast Nephropathy (EuLITE) and Studies in patients with Multiple Myeloma and Renal Failure due to Myeloma Cast Nephropathy (MYRE)—are ongoing in Europe to further assess the efficacy of these high-cutoff dialyzers in myeloma kidney failure. In a recent report, by the original authors, high-cutoff dialyzers were found to be ineffective in removing free light chains due to formation of large FLC aggregates.[25]


Transplantation has been performed successfully in patients with end-stage renal disease secondary to multiple myeloma. Consider renal transplantation only in patients who have achieved hematologic remission and who have no other major complications of their monoclonal gammopathy. Recurrent disease is common in patients with LCDD following transplantation, and renal transplantation should not be done until optimal measures have ensured substantial reduction in light chain production.


Treat infection early and effectively with nonnephrotoxic antibiotics. Intravenous immunoglobulin infusions have been used as prophylaxis against infection in the plateau phase of the disease.

Hyperviscosity may manifest as confusion and neurological symptoms. Measure plasma viscosity in these patients, and implement urgent plasmapheresis.

Provide sodium bicarbonate supplementation to effectively control acidosis.


Surgical Care

Patients with renal failure should have early, permanent vascular access because of the high risk of infection associated with temporary catheters. Refer the patient to a vascular surgeon for the placement of a permanent vascular access device.



A multidisciplinary approach is important in the treatment of these patients, and consultations with following specialists are useful:

  • Hematologist/oncologist - Treatment of the underlying disease process
  • Nephrologist - Prevention and treatment of acute and chronic renal failure
  • Infectious disease specialist - Treatment of sepsis in immunocompromised patients
  • Blood purification specialist - Plasmapheresis
  • Vascular surgeon - Placement of a permanent vascular access device for dialysis


No special restrictions are required unless the patient has chronic renal failure.

  • Optimize nutritional intake.
  • High fluid intake (2-3 L/d) is important to avoid dehydration and to minimize further cast formation.
  • Increased fluid intake is important during periods of volume depletion (eg, fever, diarrhea, vomiting).


Activity should be as tolerated by the individual.

Contributor Information and Disclosures

Malvinder S Parmar, MB, MS FRCP(C), FACP, FASN, Associate Professor, Department of Internal Medicine, Northern Ontario School of Medicine; Assistant Professor, Department of Medicine, University of Ottawa Faculty of Medicine; Consulting Physician, Timmins and District Hospital, Ontario, Canada

Malvinder S Parmar, MB, MS is a member of the following medical societies: American College of Physicians, American Society of Nephrology, Canadian Medical Association, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christie P Thomas, MBBS, FRCP, FASN, FAHA Professor, Department of Internal Medicine, Division of Nephrology, Departments of Pediatrics and Obstetrics and Gynecology, Medical Director, Kidney and Kidney/Pancreas Transplant Program, University of Iowa Hospitals and Clinics

Christie P Thomas, MBBS, FRCP, FASN, FAHA is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Nephrology, Royal College of Physicians

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FACP, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology

Disclosure: Nothing to disclose.

  1. Smithline N, Kassirer JP, Cohen JJ. Light-chain nephropathy. Renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med. 1976 Jan 8. 294(2):71-4. [Medline].

  2. Herrera GA. Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch Pathol Lab Med. 2014 Oct. 138 (10):1365-80. [Medline].

  3. Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 2015 Nov. 88 (5):1135-1143. [Medline].

  4. Niewmierzycka A, Kurman M, Leśniak M, Winiarska A, Pawłowska A. Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. Pol Arch Med Wewn. 2015. 125 (7-8):532-7. [Medline].

  5. Adams W. Mollitis ossium. Trans Pathol Soc London. 1872. 23:186.

  6. Glenner GG, Terry W, Harada M, et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science. 1971 Jun 11. 172(988):1150-1. [Medline].

  7. Kaplan B, Ramirez-Alvarado M, Sikkink L, et al. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol. 2009 Mar. 144(5):705-15. [Medline].

  8. Bate KL, Clouston D, Packham D, Ratnaike S, Ebeling PR. Lambda light chain induced nephropathy: a rare cause of the Fanconi syndrome and severe osteomalacia. Am J Kidney Dis. 1998 Dec. 32 (6):E3. [Medline].

  9. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005 May. 51(5):878-81. [Medline].

  10. Rao M, Yu WW, Chan J, Patel K, Comenzo R, Lamont JL, et al. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias. AHRQ Comparative Effectiveness Reviews. 2012 Aug. [Medline].

  11. Pérez-Suárez G, Raya JM, Alvarez A, et al. Progressive renal failure as the first manifestation of monoclonal light-chain deposition disease with rapid multiple organ involvement. Clin Nephrol. 2009 Mar. 71(3):314-7. [Medline].

  12. Uppin MS, Prayaga AK, Srinivas BH, Rapur R, Desai M, Dakshina Murthy KV. Light chain immunofluorescence in various nephropathies. Indian J Pathol Microbiol. 2011 Jan-Mar. 54(1):55-8. [Medline].

  13. Gharwan H, Truica CI. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol. 2011 Apr 9. [Medline].

  14. Firkin F, Hill PA, Dwyer K, et al. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis. 2004 Sep. 44(3):551-5. [Medline].

  15. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology. 1992 May. 183(2):519-21. [Medline].

  16. Zucchelli P, Pasquali S, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988 Jun. 33(6):1175-80. [Medline].

  17. Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990 Apr. 150(4):863-9. [Medline].

  18. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005 Dec 6. 143(11):777-84. [Medline].

  19. Leung N. Plasma exchange in multiple myeloma. Ann Intern Med. 2006 Mar 21. 144(6):455; author reply 455. [Medline].

  20. Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008 Jun. 73(11):1282-8. [Medline].

  21. Clark WF, Garg AX. Plasma exchange for myeloma kidney: cast(s) away?. Kidney Int. 2008 Jun. 73(11):1211-3. [Medline].

  22. Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011 Jun 16. 364(24):2365-6. [Medline].

  23. Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011 Jun. 22(6):1129-36. [Medline]. [Full Text].

  24. Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009 Apr. 4(4):745-54. [Medline]. [Full Text].

  25. Harding S, Provot F, Beuscart JB, et al. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol Dial Transplant. 2011 Apr. 26(4):1438. [Medline].

  26. Firkin F, Hill PA, Dwyer K, et al. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis. 2004 Sep. 44(3):551-5. [Medline].

  27. Herrera GA, Joseph L, Gu X, et al. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004 Aug. 128(8):875-9. [Medline].

  28. Jones HB. Papers on chemical pathology: Prefaced by the Gulstonian lectures, read at the Royal College of Physicians, 1846. Lancet. 1847. 2:88-92.

  29. Klassen RB, Allen PL, Batuman V, et al. Light chains are a ligand for megalin. J Appl Physiol. 2005 Jan. 98(1):257-63. [Medline].

  30. Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003 Dec. 42(6):1154-63. [Medline].

  31. Ronco PM, Alyanakian MA, Mougenot B, et al. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol. 2001 Jul. 12(7):1558-65. [Medline].

  32. Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004 Feb. 65(2):642-8. [Medline].

  33. Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease--diagnosis and treatment. Clin J Am Soc Nephrol. 2007 Jul. 2(4):858-67. [Medline].

  34. Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol. 2003 Jun. 284(6):F1245-54. [Medline].

Light chain–associated renal disorders. Light microscopy (hematoxylin and eosin stain at 25X power) showing nodular glomerulosclerosis (arrow) and thickening of the basement membrane. Courtesy of Madeleine Moussa, MD, FRCPC, Department of Pathology, London Health Sciences Centre, London, Ontario, Canada.
Light chain–associated renal disorders. Immunofluorescence (25X power) showing deposits of monotypic light chain along the basement membrane. Courtesy of Madeleine Moussa, MD, FRCPC, Department of Pathology, London Health Sciences Centre, London, Ontario, Canada.
Light chain–associated renal disorders. Ultrastructure (electron microscopy at 29,000X power) showing deposition of nonfibrillar electron-dense material in the mesangial nodule (arrow). Courtesy of Madeleine Moussa, MD, FRCPC, Department of Pathology, London Health Sciences Centre, London, Ontario, Canada.
Light chain–associated renal disorders. Ultrastructure (electron microscopy at 29,000X power) showing deposition of nonfibrillar electron-dense material along the basement membrane (arrows). Courtesy of Madeleine Moussa, MD, FRCPC, Department of Pathology, London Health Sciences Centre, London, Ontario, Canada.
Light chain–associated renal disorders. Immunoelectron microscopy (immunogold at 29,000X power) showing kappa light-chain deposition. Courtesy of Madeleine Moussa, MD, FRCPC, Department of Pathology, London Health Sciences Centre, London, Ontario, Canada.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.